Translational advances in gynecologic cancers / edited by Michael J. Birrer, Lorenzo Ceppi.

Format:

Book

Contributor:

Birrer, Michael J., editor.

Ceppi, Lorenzo, editor.

ebrary, Inc.

Louis B. Flexner Medical Book Fund.

Language:

English

Subjects (All):

Generative organs, Female--Cancer.

Generative organs, Female.

Physical Description:

1 online resource

Place of Publication:

London, United Kingdom ; San Diego, CA, United States : Academic Press, [2017]

System Details:

text file

Contents:

Front Cover; Translational Advances in Gynecologic Cancers; Copyright Page; Contents; List of Contributors; Translational Advances in Gynecologic Cancers; Introduction; I. Ovarian Cancer; 1 Origins of Epithelial Ovarian Cancer; Introduction; Embryonic Development; Serous EOC; Endometrioid EOC; Mucinous EOC; Clear Cell Carcinoma; Concluding Remarks; References; 2 Ovarian Cancer Genomics; Introduction; Low-Grade Serous Ovarian Cancer; Clear Cell Ovarian Cancer; Mucinous Ovarian Cancer; Advanced Stage Serous Ovarian Cancer; DNA Copy Number Analysis; Mutational Status; Gene Expression.

Methylation Analysis Generation of Clinically Relevant Signatures in OC; Gene Expression Signatures for Drug Sensitivity in OC; Recurrent Ovarian Cancer; Conclusion; List of Acronyms and Abbreviations; References; 3 Epigenetics; Introduction; Epigenetic Changes in Ovarian Cancer; Alterations in DNA Methylation; Histone Modifications in Ovarian Cancer; Expression and Function of Epigenome Modifying Enzymes in OC; DNA Methyltransferases (DNMTs); Chromatin Modifiers; Histone Methyltransferases and Demethylases in OC; Histone Acetylases and Deacetylases.

Functional Consequences of Epigenetic Alterations in OCTherapeutic Targeting of the OC Epigenome; DNMT Inhibitors; HDAC Inhibitors (HDACi); Conclusion; References; 4 Timing of Cytoreductive Surgery in the Treatment of Advanced Epithelial Ovarian Carcinoma; Introduction; History of Ovarian Cancer Surgery: Defining "Optimal"; The Quest for Complete Gross Resection: a Radical Approach; Chemotherapy Then and Now: When and How?; Primary Versus Interval Cytoreduction: Rationale; Interval Debulking Surgery: a Second Chance; Neoadjuvant Chemotherapy: Planned from the Start.

Predicting Surgical Success: Translational AdvancesIn Conclusion: What Now?; References; 5 Angiogenesis; Introduction; Angiogenesis; Vessel Sprouting Model; Tumor Angiogenesis; Growth Factor Pathways in Gynecologic Cancers; Antiangiogenic Therapies in Clinical Trials; Monoclonal Antibodies; Bevacizumab; Epithelial Ovarian Cancer; Endometrial Cancer; Cervical Cancer; Receptor Kinase Inhibitors; Fusion Peptibody; Combination Biologic Therapy; Resistance to Antiangiogenic Therapies; Biomarkers; Conclusion; Glossary; List Of Acronyms and Abbreviations; References.

6 Homologous Recombination and BRCA Genes in Ovarian Cancer: Clinical Perspective of Novel TherapeuticsIntroduction; HR and Double-Strand DNA Break Repair; HR and Epithelial Ovarian Cancer; Hereditary Risk; HR Pathway Alterations in Epithelial Ovarian Cancer; Prognostic Impact of HRD in Ovarian Cancer; Targeting HRD in Ovarian Cancer; PARP Inhibitors: Preclinical Experience; PARP Inhibitors: Clinical Experience; BRCA-Mutated Ovarian Cancers; BRCA Wild-Type Ovarian Cancers; Mechanisms of PARP Inhibitor Resistance; Beyond PARP Inhibitors in HRD; Cell Cycle and DNA Damage Checkpoints.

Notes:

Includes bibliographical references and index.

Electronic reproduction. Palo Alto, Calif. Available via World Wide Web.

Description based on online resource; title from digital title page (viewed on March 24, 2017).

Local Notes:

Acquired for the Penn Libraries with assistance from the Louis B. Flexner Medical Book Fund.

Other Format:

Print version: Translational advances in gynecologic cancers.

ISBN:

9780128037980

0128037989

Publisher Number:

99971410239

Access Restriction:

Restricted for use by site license.